Skip to main content

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Terminated · Phase 3 · NCT03906071

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer

At a glance

Research payments reported, 2025
$339,747
U.S. investigators named
50
Sites paid
42
Planned or actual enrollment
577

About the trial

Sponsor
Mirati Therapeutics Inc. (with Bristol-Myers Squibb)
Tested
Nivolumab (biological), Sitravatinib (drug), Docetaxel (drug)
Dates
Started 2019-07-15; completion 2025-09-30
Results posted
Yes

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.

From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Mirati Therapeutics, Inc. reported $339,747 in research payments for this study in 2025 (50 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.